Prehabilitation for Advanced Ovarian Cancer Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05047926|
Recruitment Status : Recruiting
First Posted : September 17, 2021
Last Update Posted : February 27, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Physical activity plays an important role in reducing the adverse effects of cancer treatment. There are few studies using prehabilitation to improve peri-operative outcomes in patients undergoing cancer surgery. This study will pilot a program of structured activity for women undergoing neoadjuvant chemotherapy with the intent to improve their physical state prior to surgical intervention and thus improve outcomes.
It has been shown that patients with advanced ovarian cancer may suffer from high levels of cancer -specific distress, depression and anxiety. It has also been proposed that psychological resilience can favorably affect psychological and treatment-related outcomes in cancer patients. Most current studied mindfulness-based interventions are limited by the time commitment required by the patient, which is difficult for patients with advanced cancer undergoing treatment, therefore a virtual program has been created that is more easily accessible.
Frailty is thought to be mediated by senescent cells and their dynamic secretome, referred to as the senescence-associated secretory phenotype (SASP). Senescent cells contribute to age-related tissue deterioration, inflammation, and fibrosis. A group of novel frailty biomarkers obtained at the time of diagnosis has been examined in advanced OC patients. Preliminary data show that these biomarkers strongly correlate with the clinical frailty phenotype, and define a frail subgroup of patients with higher treatment related morbidity and worse survival. These markers may represent important surrogate clinical trial endpoints, as well as deepen the understanding of aging in women with ovarian cancer. In this pilot, these markers and other surrogate endpoints for future novel translational research in the science of aging will be explored.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Behavioral: Exercise - Physical Activity Behavioral: Resiliency Training Dietary Supplement: Protein Supplementation||Not Applicable|
With a rapidly growing older American population, the overall incidence of cancer, including ovarian cancer (OC) is rising. Addressing aging in older OC patients represents a clinically important unmet need. Interventions designed to improve resilience against loss of function, psychological distress, complications and premature mortality in older patients are lacking in OC treatment. Current OC treatment strategies are purely tumor-directed, and do not address host factors. Our overall goal is to test whether a holistic prehabilitation program can be implemented alongside standard tumor-directed therapy in the older OC patient and will improve function, quality of life, and reduce morbidity and mortality. The 12-week period of neoadjuvant chemotherapy prior to cytoreductive surgery is an ideal window of opportunity to utilize such a strategy. Prehabilitation must be: i) practicable at the institutional level, ii) feasible at the participant level, and iii) provide demonstrable benefits.
This pilot trial will examine baseline function of all patients diagnosed with advanced ovarian cancer who are intending on curative intent treatment. Patients will have a range of assessments including functional, psychologic, and biomarkers. Patients undergoing primary debulking surgery will be in an observational arm alone. Patients undergoing neoadjuvant chemotherapy will be assigned to a trimodal prehabilitation program that involves exercise, resilience training, and nutritional support. Patient will be evaluated on this arm at baseline, prior to surgery, post-operatively and at the completion of treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Prehabilitation for Advanced Ovarian Cancer Patients|
|Actual Study Start Date :||October 1, 2021|
|Estimated Primary Completion Date :||June 15, 2023|
|Estimated Study Completion Date :||September 15, 2023|
No Intervention: Primary Cytoreductive Surgery
Women diagnosed with or having a high suspicion for ovarian cancer and undergoing primary surgical intervention for debulking of tumor.
Experimental: Neoadjuvant Chemotherapy prior to Cytoreductive Surgery
Women diagnosed with or having a high suspicion for ovarian cancer and recommended to have Neoadjuvant Chemotherapy (NACT) prior to undergoing an interval debulking surgical intervention.
Behavioral: Exercise - Physical Activity
The recommended exercise program will consist walking for 30 mins per day, 3 days per week, at any pace in any environment. In addition the subjects will be given resistance bands and instruction on following the REST program, a home-based upper and lower body strength program that uses resistance bands to improve strength and balance.
Behavioral: Resiliency Training
The Resilient Living program is modified from the Stress Management and Resiliency Training (SMART) program; which has been shown to be effective in improving resiliency, perceived stress, anxiety, and overall quality of life in a variety of populations.
Dietary Supplement: Protein Supplementation
Increased protein intake is recommended for persons with advance cancer due to malnutrition and low albumin levels. Protein intake recommendations are 1.2 -1.5 g/kg/day. A daily protein recommendation will be calculated at the time of enrollment and subjects will be allowed to select their preferred protein supplement.
- Exercise compliance [ Time Frame: 9 weeks ]This will evaluate patients ability to follow the prehabilitation program. Each day in which the participant completed >75% of the recommended exercise will be counted as compliant. The goal will be 60% compliance over the course of 9 weeks
- Nutrition compliance [ Time Frame: 9 weeks ]This will evaluate patients ability to follow the prehabilitation program. Each day in which the participant drank 75% of the recommended protein supplement will be counted as compliant. The goal will be for 60% compliance over the course of 9 weeks
- Short Physical Performance Battery differences [ Time Frame: baseline ]Short Physical Performance Battery will be evaluated at baseline between the two cohorts.
- Short Physical Performance Battery change [ Time Frame: 26 weeks +/- 12 weeks ]Short Physical Performance Battery will be evaluated from baseline to pre-operative and baseline to end of treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer based on imaging and physician diagnosis
- Suspected Stage IIIC or IV disease based on clinician staging and imaging
- Curative intent treatment with platinum-based chemotherapy
- Planned surgical intervention at some point during treatment course.
- Ability to read English
- No diagnosed severe cognitive impairment
- Ability to provide consent
- Ability to utilize technology to watch online modules for the Resilient Living Program
- Hemiplegia or paraplegia
- Current pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05047926
|Contact: Karen P Ishitani, MSNemail@example.com|
|Contact: Maureen A Lemens, BSNfirstname.lastname@example.org|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Karen P Ishitani, MSN, RN 507-538-5535 email@example.com|
|Contact: Clinical Trials Referral Office 855-776-0015 firstname.lastname@example.org|
|Principal Investigator: Amanika Kumar, M.D.|
|Principal Investigator:||Amanika Kumar, MD||Mayo Clinic|
|Responsible Party:||Amanika Kumar, M.D., Principal Investigator, Mayo Clinic|
|Other Study ID Numbers:||
NCI-021-09494 ( Registry Identifier: CTRP (Clinical Trials Reporting Program) )
|First Posted:||September 17, 2021 Key Record Dates|
|Last Update Posted:||February 27, 2023|
|Last Verified:||February 2023|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Fallopian Tube Cancer
Primary Peritoneal Cancer
Primary Cytoreductive Surgery
Interval Depbulking Surgery
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type